Partner with C-suite, senior executives, and leadership to guide product planning, evaluate investment opportunities and optimize asset value. Recent projects include:
• Leading commercial partnerships efforts, modeling strategic options and potential scenarios, including competitive dynamics, and guiding negotiations and deal terms in oncology and rare disease
• Guiding go-to-market plan, for company's first drug approved in the therapeutic area with launch year sales exceeding internal forecasts by 20%
• Charting roadmap for product commercialization strategy for a new specialty product in a $1.3B market
• Informing asset prioritization for portfolio planning, building business cases, and sizing risk adjusted market potential for each opportunity
• Guiding design of a US payer strategy that, despite intense competitive pressure and payer consolidation, ensures strong strong patient and provider access despite near-term competitor introductions

Led strategic planning, reporting to C-suite. Spearheaded cross-functional task force implementing growth initiatives, for portfolio, partnership and platform expansion, driving Pfenex's valuation +300% and delivering a $0.5B acquisition.
• Headed global strategy for portfolio of 13 drugs across early discovery, preclinical, and approved phases in rare disease, oncology, endocrinology, and infectious disease
• Drove due diligence of 66 opportunities, resulting in a $300M Merck & Co partnership and $200M Jazz Pharma collaboration. Advised deal terms, structure, and negotiations. Built business cases with valuation models and scenario analysis.
• Established and led Corporate Analysis & Review stage-gated process, prioritizing market opportunities of corporate interest
• Steered transition from a clinical to a commercial stage company, developing go-to-market plan for first FDA-approved product, which exceeded sales expectations by 20%

Served as trusted advisor to life science companies, collaborating with clients' cross-functional teams on multiyear projects, fueling growth. Engagements include:
• Expanded pipeline from a single rare disease drug to a $1 B+ platform of 10 peptides and 5 formulations in development for inflammatory, metabolic, CNS, ophthalmology, oncology, and cardiovascular diseases
• Devised lifecycle management plan, sequencing rollout of next generation drugs with incremental dosing and administration benefits to protect from loss of exclusivity and boost revenue 23%
• Created differentiated brand positioning for 3 in-line drug in one disease category, targeting distinct patient subsegments, delivering an additional $350M in annual sales
• Developed strategy to broaden treatment's application, tripling sales potential and supporting a $44M Series up-round from VC firms

Guided US commercial strategy and portfolio planning for 350 in-line and 120 pipeline products across oral, injectable, inhalant, topical, and transdermal formulations generating $4B revenue.
• Informed market dynamics and competitive trends integrating them into new business strategy initiatives, including value of volume analysis, which sized impact of shifting to high-value drugs
• Led strategic business planning, delivering US 5-year long-range forecast and annual operating plans for portfolio of products across retail and institutional channels
• Conducted due diligence on licensing and acquisition strategic opportunities and quantified near- and long-term value-add of transactions
• Led business intelligence, competitive intelligence, forecasting, and market assessments driving pipeline management, new product launch success and portfolio growth

Led consulting projects delivering recommendations on acquisitions, in-licensing, and partnerships for biopharmaceutical companies.
● • Built customized dynamic forecasts, valuations, and scenario models for drug opportunities ranging from $100M to $2B in sales potential
• Identified opportunity and mitigated risks for assets by highlighting potential impact of key levers, including internal factors (e.g. product attributes) and external forces (e.g. market dynamics)
• Informed strategic recommendations on investment decision by integrating insights from key stakeholders, including key opinion leaders, payers, and physicians

Delivered business intelligence and co-authored syndicated disease area analyst reports on the market outlook for CNS treatments in the US, Europe and Japan.